UBIP
Live / Registered — Registered (as of 25 Mar 2025)
What this means for you
Registered since 25 Mar 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97470141
- Registration number
- 7739637
- Mark type
- Design + words
- Filed
- 22 Jun 2022
- Published for opposition
- 18 Jul 2023
- Registered
- 25 Mar 2025
- Attorney of record
- Joe McKinney Muncy
Goods and services
- Class 005 — Pharmaceuticals: Antibiotics; Pre-filled syringes for medical purposes being syringes sold filled with pharmaceutical preparations for the treatment of cancers, infections, metabolic diseases, and neurological disorders; Medicines for human purposes for the treatment of cancers, infections, metabolic diseases, and neurological disorders; Contrast medium for medical use being contrast media for in vivo imaging; Ointments for pharmaceutical purposes being anti-biotic, anti-infective, and anti-inflammatory ointments; Poultices for pharmaceutical purposes being anti-biotic, anti-infective, and anti-inflammatory poultices; Western medicine, namely, pharmaceutical preparations for the treatment of cancers, infections, metabolic diseases, and neurological disorders; Active pharmaceutical ingredients (APIs) for Western Medicine being pharmaceutical preparations for the treatment of cancers, infections, metabolic diseases, and neurological disorders; Vitamin preparations; antiviral drug; biological preparations for medical purposes being biological preparations for the treatment of cancers, infections, metabolic diseases, neurological disorders; Hormones for medical purposes; Medicated skin lotions for pharmaceutical purposes; Medicinal drinks; Vaccines; chemico-pharmaceutical preparations for the treatment of cancers, infections, metabolic diseases, neurological disorders; Albuminous preparations for medical purposes, namely, pharmaceutical preparations featuring albumin peptides, proteins and complexes thereof for the treatment of cancers, infections, metabolic diseases, and neurological disorders; biological reagent for medical purposes; test reagent for medical purposes; Diagnostic preparations for medical purposes; Diagnostic biomarker reagents for medical purposes
- Class 042 — Scientific and technological services: Providing research and development in the field of biological and pharmaceutical scientific research and development; Biological research; Bacteriological research; Clinical lab test of medical reagent being providing reagent sample testing for others for scientific research purposes; Clinical trials, namely, scientific research in the nature of conducting clinical trials for others; Research and analysis of medical reagent being medical research; medical research; Research and development of new products for others; Technical project studies being conducting of feasibility studies in the field of new technologies; Technical writing; Industrial analysis and research service in the field of pharmaceutical sciences; Rental of laboratory instruments; Scientific laboratory services; Technological consultancy in the field of biological and pharmaceutical manufacturing processes; scientific research and technological research in the field of biological and pharmaceutical manufacturing processes; culturing of cells for others for scientific research purposes
Owner
- UBI Pharma Inc., Hsinchu County, TW
- UBI Pharma Inc., Hsinchu County, TW
- UBI Pharma Inc., Hsinchu County, TW
Prosecution history
- 25 Mar 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 25 Mar 2025 — REGISTERED-PRINCIPAL REGISTER
- 03 Mar 2025 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 03 Mar 2025 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 14 Feb 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 14 Feb 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 14 Feb 2025 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 15 Nov 2024 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 15 Nov 2024 — FINAL REFUSAL E-MAILED
- 15 Nov 2024 — SU - FINAL REFUSAL - WRITTEN
- 22 Oct 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 22 Oct 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 22 Oct 2024 — ASSIGNED TO LIE
- 11 Jul 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 12 Apr 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED